APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuromuscular Blocking Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuromuscular Blocking Drug Market Outlook and Growth Opportunities 2026

2 January 2026193 pages

Choose your research edition.

Industry ResearchNeuromuscular Blocking Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromuscular Blocking Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Neuromuscular Blocking Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromuscular Blocking Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromuscular Blocking Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Neuromuscular Blocking Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuromuscular Blocking Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuromuscular Blocking Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuromuscular Blocking Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuromuscular Blocking Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuromuscular Blocking Drug market include Hikma Pharmaceuticals, AbbVie, Bayer, GSK, Pfizer, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neuromuscular Blocking Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuromuscular Blocking Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuromuscular Blocking Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuromuscular Blocking Drug market.

Neuromuscular Blocking Drug Segment by Company

Hikma Pharmaceuticals

AbbVie

Bayer

GSK

Pfizer

Merck

Novartis

Neuromuscular Blocking Drug Segment by Type

Non-polarizing Agents

Depolarizing Agents

Neuromuscular Blocking Drug Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Neuromuscular Blocking Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neuromuscular Blocking Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neuromuscular Blocking Drug key companies, revenue, market share, and recent developments.

3. To split the Neuromuscular Blocking Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neuromuscular Blocking Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuromuscular Blocking Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Neuromuscular Blocking Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromuscular Blocking Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromuscular Blocking Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromuscular Blocking Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuromuscular Blocking Drug industry.

Chapter 3: Detailed analysis of Neuromuscular Blocking Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neuromuscular Blocking Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neuromuscular Blocking Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuromuscular Blocking Drug Industry Trends Table 2. Neuromuscular Blocking Drug Industry Drivers Table 3. Neuromuscular Blocking Drug Industry Opportunities and Challenges Table 4. Neuromuscular Blocking Drug Industry Restraints Table 5. Global Neuromuscular Blocking Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuromuscular Blocking Drug Revenue Share by Company (2021-2026) Table 7. Global Neuromuscular Blocking Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neuromuscular Blocking Drug Key Company Manufacturing Base & Headquarters Table 9. Global Neuromuscular Blocking Drug Company, Product Type & Application Table 10. Global Neuromuscular Blocking Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neuromuscular Blocking Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-polarizing Agents Table 15. Significant Companies of Depolarizing Agents Table 16. Global Neuromuscular Blocking Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Neuromuscular Blocking Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Neuromuscular Blocking Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Neuromuscular Blocking Drug Sales Value Share by Type (2021-2026) Table 20. Global Neuromuscular Blocking Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Pharmacy Table 22. Significant Companies of Online Pharmacy Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Others Table 25. Global Neuromuscular Blocking Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuromuscular Blocking Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Neuromuscular Blocking Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Neuromuscular Blocking Drug Sales Value Share by Application (2021-2026) Table 29. Global Neuromuscular Blocking Drug Sales Value Share by Application (2027-2032) Table 30. Global Neuromuscular Blocking Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neuromuscular Blocking Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Neuromuscular Blocking Drug Sales Value Share by Region (2021-2026) Table 33. Global Neuromuscular Blocking Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Neuromuscular Blocking Drug Sales Value Share by Region (2027-2032) Table 35. Global Neuromuscular Blocking Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neuromuscular Blocking Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Neuromuscular Blocking Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Neuromuscular Blocking Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Neuromuscular Blocking Drug Sales Value Market Share by Country (2027-2032) Table 40. Hikma Pharmaceuticals Company Information Table 41. Hikma Pharmaceuticals Business Overview Table 42. Hikma Pharmaceuticals Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Hikma Pharmaceuticals Neuromuscular Blocking Drug Product Portfolio Table 44. Hikma Pharmaceuticals Recent Development Table 45. AbbVie Company Information Table 46. AbbVie Business Overview Table 47. AbbVie Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. AbbVie Neuromuscular Blocking Drug Product Portfolio Table 49. AbbVie Recent Development Table 50. Bayer Company Information Table 51. Bayer Business Overview Table 52. Bayer Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bayer Neuromuscular Blocking Drug Product Portfolio Table 54. Bayer Recent Development Table 55. GSK Company Information Table 56. GSK Business Overview Table 57. GSK Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GSK Neuromuscular Blocking Drug Product Portfolio Table 59. GSK Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Neuromuscular Blocking Drug Product Portfolio Table 64. Pfizer Recent Development Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck Neuromuscular Blocking Drug Product Portfolio Table 69. Merck Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Neuromuscular Blocking Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis Neuromuscular Blocking Drug Product Portfolio Table 74. Novartis Recent Development Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Neuromuscular Blocking Drug Product Image Figure 2. Global Neuromuscular Blocking Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuromuscular Blocking Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuromuscular Blocking Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-polarizing Agents Image Figure 8. Depolarizing Agents Image Figure 9. Global Neuromuscular Blocking Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Neuromuscular Blocking Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Neuromuscular Blocking Drug Sales Value Share by Type (2021-2032) Figure 12. Hospital Pharmacy Image Figure 13. Online Pharmacy Image Figure 14. Retail Pharmacy Image Figure 15. Others Image Figure 16. Global Neuromuscular Blocking Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuromuscular Blocking Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neuromuscular Blocking Drug Sales Value Share by Application (2021-2032) Figure 19. Global Neuromuscular Blocking Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Neuromuscular Blocking Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Neuromuscular Blocking Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Neuromuscular Blocking Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Neuromuscular Blocking Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Neuromuscular Blocking Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Neuromuscular Blocking Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Neuromuscular Blocking Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Neuromuscular Blocking Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Neuromuscular Blocking Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Neuromuscular Blocking Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Neuromuscular Blocking Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Non-polarizing Agents
  • Depolarizing Agents
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Hikma Pharmaceuticals
  • AbbVie
  • Bayer
  • GSK
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuromuscular Blocking Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuromuscular Blocking Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neuromuscular Blocking Drug Market Dynamics
  1. 2.1 Neuromuscular Blocking Drug Industry Trends
  2. 2.2 Neuromuscular Blocking Drug Industry Drivers
  3. 2.3 Neuromuscular Blocking Drug Industry Opportunities and Challenges
  4. 2.4 Neuromuscular Blocking Drug Industry Restraints
3 Neuromuscular Blocking Drug Market by Company
  1. 3.1 Global Neuromuscular Blocking Drug Company Revenue Ranking in 2025
  2. 3.2 Global Neuromuscular Blocking Drug Revenue by Company (2021-2026)
  3. 3.3 Global Neuromuscular Blocking Drug Company Ranking (2024-2026)
  4. 3.4 Global Neuromuscular Blocking Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Neuromuscular Blocking Drug Company Product Type and Application
  6. 3.6 Global Neuromuscular Blocking Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neuromuscular Blocking Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neuromuscular Blocking Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neuromuscular Blocking Drug Market by Type
  1. 4.1 Neuromuscular Blocking Drug Type Introduction
  2. 4.1.1 Non-polarizing Agents
  3. 4.1.2 Depolarizing Agents
  4. 4.2 Global Neuromuscular Blocking Drug Sales Value by Type
  5. 4.2.1 Global Neuromuscular Blocking Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neuromuscular Blocking Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Neuromuscular Blocking Drug Sales Value Share by Type (2021-2032)
5 Neuromuscular Blocking Drug Market by Application
  1. 5.1 Neuromuscular Blocking Drug Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Retail Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Neuromuscular Blocking Drug Sales Value by Application
  7. 5.2.1 Global Neuromuscular Blocking Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuromuscular Blocking Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Neuromuscular Blocking Drug Sales Value Share by Application (2021-2032)
6 Neuromuscular Blocking Drug Regional Value Analysis
  1. 6.1 Global Neuromuscular Blocking Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuromuscular Blocking Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neuromuscular Blocking Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neuromuscular Blocking Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuromuscular Blocking Drug Sales Value (2021-2032)
  7. 6.3.2 North America Neuromuscular Blocking Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neuromuscular Blocking Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Neuromuscular Blocking Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neuromuscular Blocking Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neuromuscular Blocking Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neuromuscular Blocking Drug Sales Value (2021-2032)
  16. 6.6.2 South America Neuromuscular Blocking Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neuromuscular Blocking Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neuromuscular Blocking Drug Sales Value Share by Country, 2025 VS 2032
7 Neuromuscular Blocking Drug Country-level Value Analysis
  1. 7.1 Global Neuromuscular Blocking Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuromuscular Blocking Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neuromuscular Blocking Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neuromuscular Blocking Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neuromuscular Blocking Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neuromuscular Blocking Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neuromuscular Blocking Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hikma Pharmaceuticals
  2. 8.1.1 Hikma Pharmaceuticals Company Information
  3. 8.1.2 Hikma Pharmaceuticals Business Overview
  4. 8.1.3 Hikma Pharmaceuticals Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Hikma Pharmaceuticals Neuromuscular Blocking Drug Product Portfolio
  6. 8.1.5 Hikma Pharmaceuticals Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Neuromuscular Blocking Drug Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Neuromuscular Blocking Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Neuromuscular Blocking Drug Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Neuromuscular Blocking Drug Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Neuromuscular Blocking Drug Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Neuromuscular Blocking Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Neuromuscular Blocking Drug Product Portfolio
  42. 8.7.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst